TABLE 1.
Clinical doses of irrational β-lactam–β-lactamase inhibitor combinations available in India and Chinaa
| BL-BLI combination | Clinical dose (mg) of: |
|
|---|---|---|
| BL | BLI | |
| Ceftriaxone-tazobactamb | 1,000 | 125 |
| 500 | 62.5 | |
| 250 | 31.25 | |
| Ceftazidime-tazobactamb | 1,000 | 125 |
| 500 | 62.5 | |
| 250 | 31.25 | |
| Cefoperazone-tazobactamb | 1,000 | 125 |
| 500 | 62.5 | |
| Cefepime-tazobactam | 1,000 | 125 |
| 500 | 62.5 | |
| Cefotaxime-sulbactamb | 1,000 | 500 |
| 500 | 250 | |
| 250 | 125 | |
| Ceftriaxone-sulbactamb | 1,000 | 500 |
| 500 | 250 | |
| 250 | 125 | |
| Ceftriaxone-sulbactam + EDTA at 37 mg (CSE 1034) | 1,000 | 500 |
| Cefepime-sulbactam | 1,000 | 500 |
| Meropenem-sulbactam | 1,000 | 500 |
a
BL, β-lactam; BLI, β-lactamase inhibitor; EDTA, ethylenediaminetetraacetic acid. All tazobactam-based combinations are in an 8:1 ratio, like that of piperacillin-tazobactam. All sulbactam-based combinations are in a 2:1 ratio, like that of ampicillin-sulbactam.
b
Combination available in China.